Q4 2018 Bellicum Pharmaceuticals Inc Earnings Call
שיחת ועידה Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals Inc Conference call will be held on 12/03/2019. During the earnings conference call's session Bellicum Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Bellicum Pharmaceuticals Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. Cellular immunotherapy has the potential to transform medicine by harnessing immune cells, principally T cells, to attack and eliminate harmful diseased cells in the body. Unlike traditional small molecule and biologic therapies, which are predictably metabolized and eliminated from the body, cellular immunotherapies are unpredictable and uncontrollable. We are using our proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and then control components of the immune system. By incorporating our CID platform, our product candidates may offer better safety and efficacy outcomes than are seen with current cellular immunotherapies.קרא עוד שיחת ועידה